31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstractsSonja Althammer, Scott Antonia, Brandon W. Higgs et al.|Journal for ImmunoTherapy of Cancer|2016Cited by 17
A phase II prospective study of gemcitabine and platin-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG studyStéphane Culine, F. Rolland, Stéphane Oudard et al.|Journal of Clinical Oncology|2005Cited by 3
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patientsCécile Vicier, Karim Fizazi, Laurence Faivre et al.|Annals of Oncology|2016Cited by 0